Press release
Pancreatic Ductal Adenocarcinoma Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therap
Pancreatic Ductal Adenocarcinoma Pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analyzes DelveInsight.Pancreatic Ductal Adenocarcinoma Overview:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a 5-year survival rate of under 10%. Most patients are diagnosed when the disease is already advanced, locally unresectable, or metastatic. The poor prognosis of PDAC is largely due to its complex, multifactorial nature. Early detection is challenging because symptoms typically do not manifest until the cancer has progressed and spread to other areas. Treatment of pancreatic cancer is hindered by both genetic and cellular factors. The significant mutational alterations in pancreatic tumors lead to gene instability, which plays a crucial role in the tumor's growth and its resistance to therapies.
Download our report @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Ductal Adenocarcinoma Therapeutics Market.
Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report
DelveInsight's Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
On March 26, 2025, the FDA approved cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors, based on data from the phase 3 CABINET study.
On December 4, 2024, the FDA approved zenocutuzumab for patients with NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma.
In June 2024, the FDA granted fast track designation to IBI343 for the treatment of advanced or metastatic PDAC.
Key Pancreatic Ductal Adenocarcinoma companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others are evaluating new drugs for Pancreatic Ductal Adenocarcinoma to improve the treatment landscape.
Promising Pancreatic Ductal Adenocarcinoma pipeline therapies in various stages of development include Onvansertib, Nadunolimab, Zimberelimab, and others.
Pancreatic Ductal Adenocarcinoma Pipeline Analysis
The Pancreatic Ductal Adenocarcinoma pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Pancreatic Ductal Adenocarcinoma Market.
Categorizes Pancreatic Ductal Adenocarcinoma therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Pancreatic Ductal Adenocarcinoma drugs under development based on:
Stage of development
Pancreatic Ductal Adenocarcinoma Route of administration
Target receptor
Monotherapy vs. combination therapy
Pancreatic Ductal Adenocarcinoma Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Pancreatic Ductal Adenocarcinoma Licensing agreements
Funding and investment activities supporting future Pancreatic Ductal Adenocarcinoma market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pancreatic Ductal Adenocarcinoma Emerging Drugs
Onvansertib: Cardiff Oncology
Nadunolimab: Cantargia
Zimberelimab: Arcus Biosciences
Pancreatic Ductal Adenocarcinoma Companies
There are over 80 major companies working on therapies for Pancreatic Ductal Adenocarcinoma. Among them, XOMA is one of the companies with drug candidates for this condition in the most advanced stage, specifically Phase III.
DelveInsight's report covers around 140+ products under different phases of Pancreatic Ductal Adenocarcinoma clinical trials like
Pancreatic Ductal Adenocarcinoma Late stage Therapies (Phase III)
Pancreatic Ductal Adenocarcinoma Mid-stage Therapies (Phase II)
Pancreatic Ductal Adenocarcinoma Early-stage Therapies (Phase I)
Pancreatic Ductal Adenocarcinoma Pre-clinical and Pancreatic Ductal Adenocarcinoma Discovery stage Therapies
Pancreatic Ductal Adenocarcinoma Discontinued & Inactive Therapies
Pancreatic Ductal Adenocarcinoma pipeline report provides the Pancreatic Ductal Adenocarcinoma therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Ductal Adenocarcinoma Therapies and Key Pancreatic Ductal Adenocarcinoma Companies: Pancreatic Ductal Adenocarcinoma Clinical Trials and recent advancements https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment
• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
Download Pancreatic Ductal Adenocarcinoma Sample report to know in detail about the Pancreatic Ductal Adenocarcinoma treatment market @ Pancreatic Ductal Adenocarcinoma Therapeutic Assessment https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns
4. Pancreatic Ductal Adenocarcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma Late-Stage Products (Phase-III)
7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Ductal Adenocarcinoma Discontinued Products
13. Pancreatic Ductal Adenocarcinoma Product Profiles
14. Pancreatic Ductal Adenocarcinoma Key Companies
15. Pancreatic Ductal Adenocarcinoma Key Products
16. Dormant and Discontinued Products
17. Pancreatic Ductal Adenocarcinoma Unmet Needs
18. Pancreatic Ductal Adenocarcinoma Future Perspectives
19. Pancreatic Ductal Adenocarcinoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Pancreatic Ductal Adenocarcinoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Ductal Adenocarcinoma Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therap here
News-ID: 3965937 • Views: …
More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…

Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…

Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…

Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Pancreatic
Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate?
There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value…
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth
Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of…
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025
Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025
Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Pancreatic Market to Insight By 2025: Top Key Vendors
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to…